Every Other Week: Stretching the Interval

There are three different ways to use less drug, and they keep getting confused. You can take a smaller dose below the labeled range — microdosing, which has no trials. You can step down to a lower labeled dose — tested and randomized. Or you can keep the same dose and stretch the interval. A 2026 report looked at the third, and it is a case series.

What was observed

Patients who had plateaued on weekly semaglutide or tirzepatide were moved to reduced-frequency dosing — usually every other week — at their existing dose, and followed for an average of 36.3 weeks.^[1]

Weight did not merely hold — it fell slightly further. Total body fat and truncal fat declined, skeletal muscle mass stabilized, and the metabolic improvements gained during weekly dosing were maintained.^[1]

Why this cannot carry the weight people will put on it

A case series is a description of what happened to a group of patients someone chose to write up. There is no control group, no randomization, and no comparator arm continuing weekly dosing alongside them.

• Selection. Clinicians move patients who are doing well onto reduced frequency. Patients doing well continue doing well. That alone could produce this entire result.
• No counterfactual. Nobody knows what these same patients would have weighed had they stayed weekly — possibly less.
• Everyone had already plateaued. This says nothing about stretching the interval during active weight loss, which is when most people would want to.
• Small and unblinded, with outcomes measured in a clinic that chose the intervention.

“Reduced-frequency dosing maintains weight” is exactly the sentence a cheaper subscription tier wants. A case series cannot supply it.

Why it is still worth knowing

Because the underlying idea is pharmacologically reasonable and under-tested. These drugs have long half-lives — semaglutide’s is about a week — so a fortnightly interval is not the same as a fortnight without drug. Enough remains between doses that the concept is not absurd, and the randomized dose-reduction evidence points the same general way: less drug held much of the loss.

It also matters practically. Cost is the single commonest reason people stop, and stopping entirely produces a much worse outcome than any reduced-intensity strategy tested so far. A structured de-escalation supervised by a prescriber is a genuinely different thing from quietly stretching doses to make a vial last, and this report is an argument for studying the first properly rather than for improvising the second.